Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/09/2022 | 14.86% | Goldman Sachs | $14 → $16 | Maintains | Neutral |
08/02/2022 | 0.5% | Goldman Sachs | $16 → $14 | Maintains | Neutral |
09/22/2021 | 230.22% | Goldman Sachs | → $46 | Downgrades | Buy → Neutral |
08/03/2021 | 273.3% | Jefferies | → $52 | Initiates Coverage On | → Buy |
03/13/2020 | — | Cantor Fitzgerald | Initiates Coverage On | → Overweight | |
02/20/2020 | 172.79% | Goldman Sachs | → $38 | Initiates Coverage On | → Buy |
11/19/2019 | — | CLSA | Initiates Coverage On | → Buy | |
10/23/2019 | — | B of A Securities | Reinstates | → Buy | |
03/04/2019 | — | Deutsche Bank | Initiates Coverage On | → Buy | |
10/17/2017 | 172.79% | Canaccord Genuity | $30 → $38 | Maintains | Buy |
HUTCHMED (China) Questions & Answers
The latest price target for HUTCHMED (China) (NASDAQ: HCM) was reported by Goldman Sachs on August 9, 2022. The analyst firm set a price target for $16.00 expecting HCM to rise to within 12 months (a possible 14.86% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for HUTCHMED (China) (NASDAQ: HCM) was provided by Goldman Sachs, and HUTCHMED (China) maintained their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HUTCHMED (China), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HUTCHMED (China) was filed on August 9, 2022 so you should expect the next rating to be made available sometime around August 9, 2023.
While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a maintained with a price target of $14.00 to $16.00. The current price HUTCHMED (China) (HCM) is trading at is $13.93, which is out of the analyst's predicted range.